- Home
- BSII vs BWAY Comparison
BSII vs BWAY Comparison
Compare BSII & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSII
- BWAY
- Stock Information
- Founded
- BSII 2024
- BWAY 2003
- Country
- BSII Hong Kong
- BWAY Israel
- Employees
- BSII N/A
- BWAY N/A
- Industry
- BSII
- BWAY Medical/Dental Instruments
- Sector
- BSII
- BWAY Health Care
- Exchange
- BSII Nasdaq
- BWAY Nasdaq
- Market Cap
- BSII 189.9M
- BWAY 177.4M
- IPO Year
- BSII 2024
- BWAY 2019
- Fundamental
- Price
- BSII $9.95
- BWAY $10.23
- Analyst Decision
- BSII
- BWAY Strong Buy
- Analyst Count
- BSII 0
- BWAY 3
- Target Price
- BSII N/A
- BWAY $13.17
- AVG Volume (30 Days)
- BSII 296.0
- BWAY 49.6K
- Earning Date
- BSII 01-01-0001
- BWAY 03-05-2025
- Dividend Yield
- BSII N/A
- BWAY N/A
- EPS Growth
- BSII N/A
- BWAY N/A
- EPS
- BSII N/A
- BWAY 0.04
- Revenue
- BSII N/A
- BWAY $38,631,000.00
- Revenue This Year
- BSII N/A
- BWAY $388.82
- Revenue Next Year
- BSII N/A
- BWAY $18.70
- P/E Ratio
- BSII N/A
- BWAY $129.57
- Revenue Growth
- BSII N/A
- BWAY 34.19
- 52 Week Low
- BSII $10.05
- BWAY $4.61
- 52 Week High
- BSII $10.30
- BWAY $10.98
- Technical
- Relative Strength Index (RSI)
- BSII N/A
- BWAY 61.17
- Support Level
- BSII N/A
- BWAY $9.18
- Resistance Level
- BSII N/A
- BWAY $9.75
- Average True Range (ATR)
- BSII 0.00
- BWAY 0.34
- MACD
- BSII 0.00
- BWAY 0.11
- Stochastic Oscillator
- BSII 0.00
- BWAY 88.67
About BSII Black Spade Acquisition II Co Class A Ordinary Share
Black Spade Acquisition II Co is a blank check company.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.